{"entity":{"id":"nct07112196","kind":"trial","name":"Visugromab in Cachexia International Trial","aka":["VINCIT"],"tldr":"A phase 2/3 trial of Visugromab, run by CatalYm GmbH, now recruiting.","summary":"Visugromab in Cachexia International Trial is a phase 2/3 interventional study registered as NCT07112196 by CatalYm GmbH, with 518 participants planned, started 2026-04-16. Conditions listed: Cancer-associated Cachexia. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07112196","url":"https://clinicaltrials.gov/study/NCT07112196"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["visugromab"],"companies":["catalym"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07112196","phase":"2/3","setting":"Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia","sponsor":"CatalYm GmbH","started":"2026-04-16","startedType":"actual","enrolled":518,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07112196/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/"}],"company":[{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/"}]}}